{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:16:59Z","timestamp":1791649019317,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["955756"],"award-info":[{"award-number":["955756"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xphs.2024.06.014","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T20:53:47Z","timestamp":1718916827000},"page":"2940-2946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Stratified Analysis of Supersaturation and Precipitation Effects Based on the Refined Developability Classification System (rDCS)"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-0865","authenticated-orcid":false,"given":"Kristian","family":"Beran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-3107","authenticated-orcid":false,"given":"Eline","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4894-7765","authenticated-orcid":false,"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia","family":"Sepassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xphs.2024.06.014_bib0001","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.xphs.2018.03.030","article-title":"A refined developability classification system","volume":"107","author":"Rosenberger","year":"2018","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.06.014_bib0002","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.xphs.2018.10.044","article-title":"Application of a refined developability classification system","volume":"108","author":"Rosenberger","year":"2019","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2024.06.014_bib0003","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2024.06.014_bib0004","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/pharmaceutics15071909","article-title":"Projection of target drug particle size in oral formulations using the refined developability classification system (rDCS)","volume":"15","author":"Beran","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.xphs.2024.06.014_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2024.06.014_bib0006","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejps.2017.04.024","article-title":"Evaluating the predictability of the in vitro transfer model and in vivo rat studies as a surrogate to investigate the supersaturation and precipitation behaviour of different Albendazole formulations for humans","volume":"105","author":"Ruff","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2024.06.014_bib0007","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1021\/acs.molpharmaceut.7b00198","article-title":"Validation of dissolution testing with biorelevant media: an OrBiTo study","volume":"14","author":"Mann","year":"2017","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.xphs.2024.06.014_bib0008","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1016\/j.xphs.2020.04.023","article-title":"Biorelevant two-stage in vitro testing for rDCS classification and in PBPK modeling\u2013case example ritonavir","volume":"109","author":"Fiolka","year":"2020","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.014_bib0009","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2024.06.014_bib0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jphp.12951","article-title":"In vitro methods to assess drug precipitation in the fasted small intestine - a PEARRL review","volume":"71","author":"O'Dwyer","year":"2019","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.014_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.2042-7158.1998.tb03303.x","article-title":"Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide","volume":"50","author":"Jung","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2024.06.014_bib0012","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpb.2016.03.011","article-title":"A heuristic model to quantify the impact of excess cyclodextrin on oral drug absorption from aqueous solution","volume":"102","author":"Olesen","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2024.06.014_bib0013","doi-asserted-by":"crossref","DOI":"10.1590\/S0104-66322008000200005","article-title":"Enhancement of solubility of albendazole by complexation with \u03b2-cyclodextrin","volume":"25","author":"Moriwaki","year":"2008","journal-title":"Brazil J Chem Eng"},{"key":"10.1016\/j.xphs.2024.06.014_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105630","article-title":"Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach","volume":"157","author":"Komasaka","year":"2021","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.014_bib0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejpb.2012.12.001","article-title":"An in vitro\u2013in silico\u2013in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene","volume":"84","author":"Kambayashi","year":"2013","journal-title":"Eur J Pharmaceut Biopharmaceut"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.014_bib0016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/j.1552-4604.1996.tb04153.x","article-title":"Metoclopramide increases the bioavailability of dantrolene in spinal cord injury","volume":"36","author":"Gilman","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2024.06.014_bib0017","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpb.2016.04.004","article-title":"Characterizing the dissolution profiles of supersaturable salts, cocrystals, and solvates to enhance in vivo oral absorption","volume":"103","author":"Hisada","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2024.06.014_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106684","article-title":"A comparison of USP 2 and \u00b5DISS Profiler\u2122 apparatus for studying dissolution phenomena of ibuprofen and its salts","volume":"193","author":"Z\u00f6ller","year":"2024","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.06.014_bib0019","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/10837451003774419","article-title":"Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying (S-SMEDDS) formulation and relative bioavailability in beagle dogs","volume":"16","author":"Zhang","year":"2011","journal-title":"Pharm Dev Technol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T23:05:41Z","timestamp":1728255941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0022354924002375"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.06.014","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Stratified Analysis of Supersaturation and Precipitation Effects Based on the Refined Developability Classification System (rDCS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}